Abstract Details

Title Treatment of Severe AIDPN with Methylprednisolone, a Series of 8 Cases

Topic Peripheral Nerve

Presentation(s) P01 - (-)

Poster/Presentation
Number 130

Objective

Background BACKGROUND: These 8 patietns were all diagnosed in the traditional manner as AIDPN. They all underwent a series of tests to rule out complicating conditions. All were treated with the traditional therapies without significant improvement until the addition of methylprednisolone.

Design/Methods DESIGN/METHODS: This is a description of the clinical courses of 8 patients with similar presentations and clear response to solumedrol despite no significant improvement with multiple courses of IVIg and PLEX.

Results RESULTS: All patietns improved dramatically with the introduction of Solumedrol, previously considered a therapy that is not effective in these situations. Solumedrol was only introduced after failure of the other therapies and usually at the 4 week point in the illness when the traditional designation of AIDPN enters the grey zone between AIDPN and CIDPN. All patietns responded dramatically.

Conclusions CONCLUSIONS: Solumedrol must be considered in severe forms of AIDPN unresponseive to more traditional therapies.

Authors/Disclosures
Oliver Blanchard, MD (Mcgill University Health Center) PRESENTER	No disclosure on file
Angela L. Genge, MD (Mcgill University)	Dr. Genge has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AL-S Pharma. Dr. Genge has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amylyx. Dr. Genge has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Quralis. Dr. Genge has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MTPA. Dr. Genge has received personal compensation in the range of $0-$499 for serving as a Consultant for WAVE. Dr. Genge has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for eikonizo. Dr. Genge has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for rapa.
Michael S. Okun, MD, FAAN (University of Florida)	Dr. Okun has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH. Dr. Okun has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Parkinson's Foundation. Dr. Okun has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Okun has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NEJM Journal Watch. The institution of Dr. Okun has received research support from NIH. The institution of Dr. Okun has received research support from Parkinson's Foundation. The institution of Dr. Okun has received research support from Tourette Association of America. The institution of Dr. Okun has received research support from Michael J Fox. Dr. Okun has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��